Ashvattha

Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations

Retrieved on: 
Monday, October 9, 2023

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.
  • Ms. Thayer has more than 20 years of progressive leadership experience in clinical development operations across various therapeutic areas from Phase 1 through Phase 3.
  • She previously served as Vice President, Head of Clinical Operations at Recode Therapeutics where she established the clinical operations function at the company.
  • Prior to Recode, she led clinical operations at Global Blood Therapeutics (Pfizer), StemCells Inc, FivePrime Therapeutics (Amgen), CV Therapeutics (Gilead), Titan Pharmaceuticals and Becton Dickinson Immunocytometry Systems.

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

Retrieved on: 
Wednesday, May 31, 2023

“We are pleased to welcome Paul and Mahesh to Ashvattha,” said Jeff Cleland, Ph.D., CEO, co-founder, and Chairman of Ashvattha Therapeutics.

Key Points: 
  • “We are pleased to welcome Paul and Mahesh to Ashvattha,” said Jeff Cleland, Ph.D., CEO, co-founder, and Chairman of Ashvattha Therapeutics.
  • Prior to joining Ashvattha, Paul served as Chief Financial and Business Officer at Otonomy, a company that specialized in developing therapeutics for diseases and disorders of the ear.
  • Paul received his bachelor’s degree in biomechanical engineering from Harvard University and an MBA from the Harvard Business School.
  • Mahesh holds an MBA from the Wharton School, University of Pennsylvania, and an MS from Georgia Institute of Technology.

Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023

REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that transverse tissue barriers to selectively target activated cells in regions of inflammation, today announced two preclinical data sets demonstrating the efficacy of its anti-angiogenic precision nanomedicine, D-4517.2.

Key Points: 
  • REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that transverse tissue barriers to selectively target activated cells in regions of inflammation, today announced two preclinical data sets demonstrating the efficacy of its anti-angiogenic precision nanomedicine, D-4517.2.
  • The data were shared in an oral presentation and poster at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting held on April 23-27, 2023 in New Orleans, LA.
  • This data supports the development of an oral formulation of D-4517.2 as an alternative to injections while greatly reducing the treatment burden on patients,” said Jeff Cleland, CEO, co-founder, and chairman of Ashvattha Therapeutics.
  • The data further support that systemic administration of D-4517.2 is effective in reducing neovascular lesions associated with AMD and selectively targets activated microglia and macrophages.

Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings

Retrieved on: 
Monday, April 3, 2023

Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a mouse model of hepatocellular carcinoma, a type of liver cancer

Key Points: 
  • Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a mouse model of hepatocellular carcinoma, a type of liver cancer
    Ashvattha will present preclinical data at ARVO on its oral formulation of D-4517.2, a potent anti-angiogenic nanomedicine, in a laser-induced choroidal neovascularization (CNV) mouse model, and compare its efficacy with intravitreal aflibercept
    REDWOOD CITY, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a new class of nanomedicines, today announced that the company will present preclinical data at the upcoming American Association for Cancer Research (AACR) and the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meetings.
  • The presentations will showcase the potential of Ashvattha’s pipeline of nanomedicines to transverse tissue barriers to selectively target activated cells in regions of inflammation.
  • The poster presented at AACR will be published in an online-only Proceedings supplement to the AACR journal Cancer Research on Friday, April 14.
  • Details for the presentations are as follows:
    The New Orleans Ernest N. Morial Convention Center, New Orleans, Louisiana

Ashvattha Therapeutics to Present at Biotech Showcase 2023

Retrieved on: 
Tuesday, January 3, 2023

REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, today announced that the Company will provide a corporate overview at Biotech Showcase 2023 taking place in San Francisco, California, from January 9-11, 2023.

Key Points: 
  • REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, today announced that the Company will provide a corporate overview at Biotech Showcase 2023 taking place in San Francisco, California, from January 9-11, 2023.
  • Presenter Jeffrey Cleland, Ph.D., Chairman, Chief Executive Officer and President of Ashvattha, and members of the Ashvattha senior management team will be available for one-on-one meetings throughout the conference.
  • Conference attendees should schedule meetings on the Biotech Showcase website .
  • Details for the presentation are as follows:

Ashvattha Therapeutics Announces the Appointment of Steve Maricich, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Thursday, October 20, 2022

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D., Ph.D., joined the company as chief medical officer.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D., Ph.D., joined the company as chief medical officer.
  • We are thrilled to welcome Dr. Maricich to our senior management team, said Jeff Cleland, Ph.D., chairman and CEO of Ashvattha.
  • Dr. Maricich joins Ashvattha from Calibr and Scripps BioVentures, where he served as the chief medical officer.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress

Retrieved on: 
Thursday, September 29, 2022

REDWOOD CITY, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics, today announced preclinical data presented by collaborators from Stanford University demonstrating that its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect activated macrophages and microglia with high sensitivity and specificity in an experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis (MS), in addition to being reproducibly synthesized and suitable for human use. The data were presented at the World Molecular Imaging Congress being held September 28th – October 1st, 2022, at the Miami Beach Convention Center in Miami, FL.

Key Points: 
  • The data were presented at the World Molecular Imaging Congress being held September 28th October 1st, 2022, at the Miami Beach Convention Center in Miami, FL.
  • PET imaging data was corroborated by autoradiography images, showing significantly higher signal in the lumbar spinal cord of untreated compared to treated EAE mice.
  • Human dosimetry estimates based on mouse imaging data are conducive to translation and clinical imaging of [18F]OP-801.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)

Retrieved on: 
Thursday, September 15, 2022

REDWOOD CITY, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics, today announced presentations of preclinical data on the selective uptake of its hydroxyl dendrimer-based PET tracer, [18F]OP-801, in the spines of a murine model of multiple sclerosis and a reduction in the PET signal after treatment with a hydroxyl dendrimer therapeutic (HDT) that inhibits CSF1 receptors. In addition, data on the synthesis of [18F]OP-801 suggests a reliable and high yielding method suitable for diagnostic imaging in humans. The data will be presented by scientific collaborators from Stanford University at the 2022 World Molecular Imaging Congress (WMIC), taking place at the Miami Beach Convention Center in Miami, FL, September 28 – October 1, 2022.

Key Points: 
  • In addition, data on the synthesis of [18F]OP-801 suggests a reliable and high yielding method suitable for diagnostic imaging in humans.
  • The data will be presented by scientific collaborators from Stanford University at the 2022 World Molecular Imaging Congress (WMIC), taking place at the Miami Beach Convention Center in Miami, FL, September 28 October 1, 2022.
  • Presentation details can be found below:
    [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that provides information on uptake of HDs across tissue barriers including the blood-brain barrier.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 2 Study of D-4517.2 for the Treatment of Wet AMD and DME 

Retrieved on: 
Wednesday, September 7, 2022

REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDT), today announced that the first patient has been enrolled in a two-stage Phase 2 clinical study of D-4517.2, an HDT with potent anti-VEGF activity. This study aims to evaluate the safety and efficacy of a subcutaneous (SC) injection of D-4517.2 at different dose levels in comparison to intravitreal (IVT) injection of aflibercept, an approved therapy, in patients suffering from wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). 

Key Points: 
  • We are excited to initiate the first stage of our Phase 2 study evaluating our subcutaneous anti-VEGF wet AMD and DME candidate, D-4517.2.
  • A subcutaneously administered treatment offers an at-home option that patients can administer themselves, said Jeffrey Cleland, Ph.D., Chairman, CEO and President of Ashvattha Therapeutics.
  • Best-corrected visual acuity (BCVA) in the study eye will also be measured for each patient during the 12-week treatment period.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Ashvattha Therapeutics Announces Preclinical Data at the 2022 Alzheimer’s Association International Conference (AAIC) Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity

Retrieved on: 
Monday, August 1, 2022

The data also build on previous studies and validates our hydroxyl dendrimers ability to cross the blood-brain barrier and be selectively taken up by reactive inflammatory cells.

Key Points: 
  • The data also build on previous studies and validates our hydroxyl dendrimers ability to cross the blood-brain barrier and be selectively taken up by reactive inflammatory cells.
  • By measuring the extent of [18F]OP-801 uptake in the brain, we will be able select patients with HD uptake based on PET signal.
  • These patients will then be treated with the same HD chemically linked to a drug to treat the disease.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology.